

CLINAM

European Foundation for Clinical
Nanomedicine



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

European Society
for NanoMedicine

The European Joint Conference for Nanomedicine


4th European-Conference for Clinical Nanomedicine (CLINAM 2011)

The Great Strides towards the Medicine of the Future

2nd Preliminary Programme (Status February 2011)

Including Call for prolonged Papers submission until March 10, 2011

Monday, May 23, 09.00 am – Wednesday, May 25, 2011, 4.30 pm



Conference with Foyer-Exhibition and University Village

Pre- Meetings on Sunday, May 22, 2011 General Assembly of the European Society for Nanomedicine (3 pm)
Meeting of the International Society for Nanomedicine (5.00 pm) Welcome Dinner for arrived speakers (7.45 pm)

Venue: Basel, Switzerland
congress center | basel

Organisers Office: European CLINAM-Foundation, Alemannengasse 12, CH-4016 Basel, Switzerland
Phone + 41 61 695 93 95 Fax + 41 61 695 93 90 Email clinam@clinam.org

Scientific Committee of the 4th European Conference for Clinical Nanomedicine

• **Prof. Dr. med. Patrick Hunziker**, President of the European Society for Nanomedicine, Basel (CH) (**Medical Chair**) • **Prof. Dr. Gert Storm**, Member of the Board of Trustees of the CLINAM-Foundation, Utrecht (NL) (**Scientific Chair**) • **Beat Löffler, MA**, CEO of the European Foundation for Clinical Nanomedicine, Basel (CH) • **Prof. Dr. Joachim Seelig**, Biozentrum, University, Basel (CH) • **Prof. Dr. Giacinto Scoles**, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I) • **Patrick Boisseau** Member of the Board of the European Technology Platform for Nanomedicine, Grenoble (F) • **Prof. Dr. med. Janos Szebeni**, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H) • **Prof. Dr. med. Marisa Papaluca Amati** Head of Scientific Support and Projects, European Medicines Agency, London (UK)

International Nanomedical Gathering in Europe – CLINAM, ETPN, ESF, EMA

The **European Foundation for Clinical Nanomedicine (CLINAM)** organises the 4th European Conference for Clinical Nanomedicine in collaboration with the **European Technology Platform on Nanomedicine (ETPN)**, the **European Science Foundation (ESF)**, the **European Society for Nanomedicine (ESNAM)** and the **European Medicines Agency (EMA)**. The cooperation between these non-profit organizations allows to present a full state of the art in nanomedicine in Europe comprising

- the Clinical View,
- First-hand Information on Policy Issues
- the Strategic Outlook from the Industrial Point of View
- the Research Roadmap for Europe in Nanomedicine
- Regulatory Aspects in Nanomedicine and
- Ethical implications of Nanomedicine.
- Societal and environmental impact
- The scientific and industrial roadmaps of nanomedicine,
- Policy activities to foster the advancement of nanomedicine
- Industrial opportunities and expectations
- Regulatory aspects of Nanomedicine (2 EMA Sessions)
- Strategic actions by health authorities
- The road of the translation in Nanomedicine from research to application.

Interdisciplinary Platform

CLINAM 2011 will highlight the joint European way of working together for a future healthcare-based on a cooperative approach between leading edge technology and science, research, clinical experience, policy, politics, regulations and industry stakeholders. It is the interdisciplinary platform for problem- and solution-oriented discussion between physicians, scientists of manifold faculties, engineers and all stakeholders in Nanomedicine and unifies the fragmentation in the field of nanoscience in health including all disciplines needed for the development of nanomedicine to the benefit of mankind and particularly the patient.

Clinical Topics

CLINAM 2011 reveals the limits and horizon of the promises of nanomedical tools, techniques, and materials in the context of prevalent and unsolved medical problems. The conference starts with the clinicians, reporting unsolved problems in a variety of medical disciplines. Based on these reports nanoscience-based technologies for solving these problems will be discussed.

Focus Session 2011: Infection and Inflammation

CLINAM 2011 highlights the following **Topics**: • Molecular and cellular basis of inflammation • Humoral and cellular immunity as targets for nanomedicine • Nanostructured vaccines • Nanoscale mechanisms and targets for nanomedicine in viral, bacterial and parasitic infections. **Fields**: • Rheumatic disease • Cancer • Cardiovascular disease • Gastrointestinal/hepatic disease, • Bacterial infection, • Multiresistant bacteria, • Viral infection including HIV • Parasitic infection, • Implants, • Diabetes, • Regenerative Medicine. **Tools at hand**: • In vitro diagnosis of inflammation, • Bedside diagnosis, • In vivo diagnosis, • Molecular Imaging, • Targeted therapy of inflammation in various diseases, • Preventing infection by nanostructured surfaces, • Preventing infection by nanosilver, • Prevention and therapy of viral inflammation by nanomedicine, • Therapy of bacterial infection by nanomedicine, • Therapy of parasitic infection by nanomedicine • Nanostructured vaccines for humoral and cellular immunity.

Late Breaking and Ongoing Trials

CLINAM 2011 will include a series of late breaking and ongoing trials. They provide novel results of preclinical and clinical trials and novel results on the application of nanomedicine in clinical medicine.

Target audience

The faculty includes the pioneers and opinion leaders in the fields of, medicine and nanoscience, who share their experience in an interdisciplinary and interactive manner that widens mutual understanding for both sides. The conference and the exhibition are aimed at physicians, as well as nanoscientists with a background in pharmacology, biology, physics, chemistry, biophysics, medicine materials science and engineering, This conference is also of interest for policymakers, experts from industry in the field of life sciences, developers of new tools and materials for nanomedicine, all those investigating the future potential of emerging technologies. Experts from venture companies can acquire knowledge on existing and upcoming developments and novel products in the emerging field of nanomedicine.

Preliminary Programme (Status February 2011)

Monday, May 23, 2011 (Registration from 07.45 am until 4.00 pm)

Plenum

09.00

1. Opening

Opening Address on behalf of the European Foundation for Clinical Nanomedicine

Beat Löffler, MA, CEO of the European CLINAM Foundation, Basel (CH)

Opening Address on behalf of the European Technology Platform on Nanomedicine

Bertrand Loubaton, MBA, Chairman of the ETPN and Director Pharmaceutical & Academic Research, Director Strategy, Head of Innovation and Cooperation, GE Healthcare Europe, Velizy (F)

Opening Address on behalf of European Science Foundation

Prof. Dr. Marja Makarow, Chief Executive of the European Science Foundation, Strasbourg (F)

Opening Address on Behalf of the the European Medicines Agency, (EMA) London

Prof. Dr. med. Marisa Papaluca-Amati, Head of Scientific Support and Projects European Medicines Agency, London (UK)

Opening Address on behalf of the University of Basel

Prof. Dr. med. Peter Meier-Abt, Vice Principal and Head of Research, University of Basel, Basel (CH)

09.25

Chairman

2. From Knowledge to Practice

Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH)

CLINAM Scientific Introduction

With Nanomedicine towards Personalised Medicine - Now and Future

Prof. Dr. med. Patrick Hunziker, Deputy Head of the Intensive Care Clinic of the University of Basel, and President of the European Society for Nanomedicine, Basel (CH)

09.45

Keynote Lecture

The Engineering of Nanostructures with Applications from Civil Engineering to Medical Science

Prof. Dr. Sir Harold Kroto, Nobel Laureate, Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida (USA)

10.40

Break

11.10

Chairman

3. Unsolved Medical Problems Waiting for Nanomedical Solutions (1)

Prof. Dr. med Matthias Pfisterer, University Hospital Basel (CH)

Statement 1

From Less Effective to Personalised Medicine

Dr. med. Vincenzo Costigliola, President of the European Medical Association (E.M.A.) and President of the European Association for Predictive and Preventive & Personalised Medicine, (EPMA), Brussels (B)

Statement 2

Unsolved Problems in Diabetes

Prof. Dr. med. John Pickup MA, BM, BCh, DPhil, FRCPath, Professor of Diabetes and Metabolism, Kings College, London (UK)

Statement 3

Unsolved Problems in Implantation

Prof. Dr. med. Enrique Gómez Barrera, Cirugía Ortopédica y Traumatología, Hospital "La Paz" Universidad Autónoma de Madrid, Madrid (SP)

- Statement 4 **Unsolved problems in Neurology – Alzheimer and Parkinson**
Prof. Dr. med. Jörg B. Schulz, Head of Department of Neurology, University Hospital Aachen, Aachen (D)
- 11.50 **Questions and Debate**
- 12.15 **Lunch**
- 13.45 **4. Nanoscience Technologies for Solving Medical Problems (1)**
 Chairman Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- Statement 1 **Nanotechnologies for Overcoming Cancer Resistance**
Prof. Dr. Patrick Couvreur, Director UMR CNRS 8612, Physico-chimie, Pharmacotechnie et Biopharmacie, University of Paris-Sud, Chatenay-Malabry (F)
- Statement 2 **Targeted Photo Dynamic Therapy Using Nanocarriers**
Patrick Boisseau, Coordinator of EuroNanoMed TARGET-PDT project, CEA-Leti, Grenoble (F)
- Statement 3 **Reducing Inflammation by Nanopyramids on Bone Implants**
Prof. Dr. Bert Müller, Thomas Straumann Chair for Materials Science in Medicine, Director of Biomaterials Science Center, University of Basel
- Statement 4 **Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis (GAMBA)**
Prof. Dr. Christian Plank, Institute for experimental oncology and therapy research of the Technical University of Munich, (D)
- Statement 5 **Nanotechnology Based Nano-Medical Device for the Treatment of Osteoarthritis**
Prof. Dr. Yechezkel Barenholz, Head, Lab of Membrane and Liposome Research Department of Biochemistry, Hebrew University - Hadassah Medical School, Jerusalem (IL)
- Statement 6 **The Use of Nanotechnology in Neurodegenerative Diseases, Emphasis on Parkinson**
Prof. Dr. Kostas Kostarelos, School of Pharmacy, University of London, (UK)
- Statement 7 **Thermosensitive Magnetoliposomes for MRI-guided Drug Delivery**
Dr. Laurent Lévy, CEO of Nanobiotix and Co-President of the French Technology Platform on Nanomedicine (FTPN), Paris (F)
- Statement 8 **Nano-immune Toxicology: Unmet Needs in Safety Prediction**
Prof. Dr. med. Janos Szebeni, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H)
15. 10 **Questions and Debate**
- 16.50 **Break**
- 16.20 **5. Late Breaking and Ongoing Trials in Nanomedicine (1)**
 Chairman Prof. Dr. med. Patrick Hunziker, Deputy Head of the Intensive Care Clinic of the University of Basel (CH)
- Statement 1 **Abraxane® in Pancreatic Cancer Treatment**
Dr. Neil P. Desai, Senior Vice President, Global Research & Development, Abraxis BioScience LLC, Los Angeles (USA)
- Statement 2 **Anticancer Agents Incorporating Polymer Micelles under Clinical Evaluation. Phase II: Lessons Learned from Early Clinical Trials**
Prof. Dr. med. Yasuhiro Matsumura, Chief, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa City (J)

Statement 3 **The Development of Lipid Nanoparticle Formulations for siRNA-Based Drugs**
Dr. Ian MacLachlan, *Executive Vice President and CSO, Tekmira Pharmaceuticals Corporation*
Burnaby, British Columbia (CDN)

Statement 4 **Thermal Treatment with Magnetic Nanoparticles**
Dr. rer. nat. Andreas Jordan, *CSO, magForce Nanotechnologie AG, Berlin (D)*

Statement 5 **New Development of Doxorubicin Transdrug in Hepatocellular Carcinoma**
Dr. med. Pierre Attali, *COO, Bioalliance Pharma, Paris (F)*

17.10 **Questions and Debate**

Panel & Debate

17.50 **6. EMA SESSION 1 Challenge: The Existing Regulation Environment in Relation to Nanomedicine**
Chairman Prof. Dr. Marisa Papaluca, *Head of Scientific Support and Projects European Medicines Agency, London (UK)*

Introduction

Nanotechnology is a most promising novel approach towards a modern, patient-centred therapy. It will yield tools to promote health and optimise treatment of diseases, and address unmet medical needs. Enabling nanotechnology applications to health products, finding their pathway to translation and on to the patient's bedside is an essential Regulators' task as part of their function to protect and promote Public Health. As debated in this conference, it is expected that in the long term nanotechnology will profoundly change the approach to healthcare, with an anticipated shift of paradigms and behaviours long established in the industry, authorities, clinicians and patients. - Whilst the knowledge and the potential applications evolve, it is essential to support progress and manage uncertainties with a holistic science-based approach encompassing: • fundamental and translational research, • transparent communication with healthcare stakeholders and the civil society • adaptation of risk management approaches as part of an integrated health strategy. - The evolution of the existing regulatory standards shall take in to account that nanotechnology applications encompass established as well as completely revolutionary products likely to lead – in the long term - to integrated systems that address health management as well as disease prevention, monitoring and care. Experts in regulatory matters, members from European, American, Canadian and Japanese regulatory authorities will discuss current initiatives relevant to Nanomedicine in their Regions, with focus on pathways towards translatability of nano-science in health products, and key regulatory issues for the future of Nanomedicine. [The session is organised by the European Medicines Agency](#)

4 Statements **(US-FDA, Health Canada, MHLW / NIH Japan, EU: DG SANCO)**

18.40 **Debate with the audience**

19.15 **End of First Day**

20.15 **The Official CLINAM Evening Gathering: Dinner and "The Nanomedicine Take Off" (Cultural Event)**

Tuesday, May 24, 2011 (Registration from 07.45 am until 4.00 pm)

The CLINAM 2011 Focus Sessions on Inflammation and Infection

Plenum

08.20 **7. Unsolved Medical Problems Waiting for Nanomedical Solutions (2)**
Chairman Prof. Dr. med. Hans Myhre, *Surgeon at the University Hospital, Oslo (N)*

Keynote Lecture

Inflammation: A Process at the Heart of Disease-Development and Body Defences
Prof. Dr. Jürg Tschopp, *Department of Biochemistry, University of Lausanne (CH)*

- 09.00
Statement 1 **Cancer Stem Cells and Inflammation – Friend or Foe?**
Dr. Christoph Ginestier, Research Investigator, Marseille Research Cancer Center, Marseille (F)
- Statement 2 **Inflammation in the Gastrointestinal Tract: Basics and Potential Therapeutic Interventions**
Dr. med. Bernhard Sauter, Partner GastroZentrum Hirslanden, The Hirslanden Private Clinic Group Zurich, (CH) and Adjunct Assistant Professor of Gastroenterology and Liver Diseases, Mount Sinai School of Medicine N.Y. (USA)
- Statement 3 **SIRS – The Inflammatory Killer Disease in Intensive Care Medicine: Challenges Ahead**
Prof. Dr. Didier Payen de la Garanderie, Head Département d'Anesthésie-Réanimation-SMUR, Hospital Lariboisière, Paris (F)
- Statement 4 **The Mysteries of Autoimmune Diseases in Rheumatology**
Prof. Alan Tyndall, Head of Department Rheumatology, Felix Platter Hospital, Basel (CH)
- Statement 5 **The Discovery of Plasmodium by Alphonse Laveran (1880) and Today's Global Fight Against Malaria**
Prof. Dr. med Blaise Genton, head of the tropical diseases, Polyclinics of the University of Lausanne Hospital, Lausanne, (CH) (invited)
- Statement 6 **Arteriosclerosis – A Life Threatening Inflammatory Disease**
Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine; Deputy Head of the Intensive Care Clinic of the University of Basel, (CH)

10.10 **Questions and Debate**

10.40 **Break**

2 PARALLEL SESSIONS

Parallel Session A (Hall 1)

- 11.15
Chairman **8. Nanoscience Technologies for Solving Medical Problems (2)**
Prof. Dr. Lajos P. Balogh, Editor-in-Chief, Nanomedicine, Nanotechnology, Biology and Medicine, Elsevier) and Member of the Executive Board, American Society for Nanomedicine, Amherst (USA)
- Statement 1 **Perspectives of Nanotechnology Based in Vitro Diagnostics in Inflammation**
Dr. med. Laszlo Takacs, PhD, D.Sc., CSO and Director General of BioSystems, Evry (F)
- Statement 2 **Diagnostics of Infection by Array-Technology**
Prof. Dr. Martin Hegner, Nanobiotech group CRANN; The Naughton Institute; School of Physics, Trinity College Dublin, Dublin (IRL)
- Statement 3 **Ultrasound Molecular Imaging in Precision medicine after Lessons from Preclinical Imaging**
Dr. med. François Tranquart, PhD, Director, Bracco Suisse SA, Geneva (CH)
- Statement 4 **Therapeutic Targeting of Inflammation in Chronic Inflammatory Disorders**
Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- Statement 5 **Therapeutic Targeting of Infection: Design of Nanovectors for the Targeted Delivery of Antimalarials**
Dr. Xavier Fernández-Busquets, Institute for Bioengineering of Catalonia, Barcelona Science Park, Barcelona (E)
- Statement 6 **Prophylactic and Therapeutic Modes of Topical Photodynamic Ultradeformable Archaeosomes against Leishmania Brasiliensis in Mice and Guinea pig**
Prof. Dr. Eder Lilia Romero, Director of the Nanomedicine Research Program (NRP), Universidad Nacional de Quilmes, Buenos Aires (RA)

Statement 7 **Simulation of Tailored Physical Chemical Properties of Bio Molecules**
PD. Dr. Wolfgang Wenzel, The Institute of Nanotechnology, Karlsruhe Institute of Technology, Karlsruhe (D)

12.25 **Questions & Debate**

13.00 **Lunch**

Parallel Session B (Hall 2)

11.15 **9. ETPN SESSION 1 Nanomedicine: Strategic Vision, Future Research, Needs for Funding and Policy Initiatives, Scientific and Industrial Roadmaps to the Advancement to the Benefit of the Patient**

Chairman Bertrand Loubaton, MBA, Chairman of the ETPN and Director Pharmaceutical & Academic Research, Director Strategy, Head of Innovation and Cooperation, GE Healthcare Europe, Velizy

Introduction

It is to be expected that the field of “Nanomedicine” and particularly the involved industry will undergo major challenges and changes. On the one hand new research results show the potential of nanotechnology in medicine for delivering novel effective treatments; on the other hand the translation from bench into product and to bedside is still slow and at times hindered by the different mindsets in industry, academia and clinics. Moreover, the European industry is facing competition with that from other areas of the world where public authorities often support the development of new Nanomedicine and Nanotechnologies for medicine much more generously than in Europe. This session elucidates the industrial perspective on “Nanomedicine” and provides some overview on necessary future actions in the area with the aim of also keeping Europe at the forefront of Research and Development in “Nanomedicine”. [The session is organised by the ETP Nanomedicine](#)

Statement 1 **The ETP Nanomedicine – Guiding the Strategy for Nanomedicine in Europe - The need for Consolidated Action**

Patrick Boisseau, Chairman Working Group Nano-diagnostics ETP Nanomedicine, CEA Leti, Grenoble (F)

Statement 2 **Changing Environments – How Industry Adapts and What Politics Should Do**

Dr. med. Isabelle Thizon-de Gaulle, Vice President “Scouting and Partnering R&D” France, Sanofi-Aventis, Paris (F) (to be confirmed))

The Challenge of Nanomedicine for Targeted Delivery – Translating from the Lab to Patients

Dr. med. Richard Peck, Global Head Clinical Pharmacology, F. Hoffmann-la Roche Ltd. , Welwyn Garden City, (UK)

Panel & Debate

12.00 **10. ETPN SESSION 2 The Industrial Perspective of Nanomedicine 2011 -2020**

Chairman Dr. Sebastian Lange, Managing Director ETP Nanomedicine, VDI/VDE-IT, Berlin (D)

The Questions

- What are the Challenges and Hurdles in developing Nanomedical Components and Devices?
- How will they come to market and when?
- Just another “novel technology” or is Nanomedicine the key to targeted drug delivery?
- What are the needs for implementing the industrial roadmaps in Nanomedicine?
- Will “Open Innovation” change translation and the way of industrials development of Drugs?
- How can the global market come to the “Competitive Together” to further Nanomedicine?
- What change of mindset is needed from academia to help industry to survive and vice versa?
- Are the ETPN proposed measures strong enough for Nanomedicine to be a dominant issue in the Framework- and Funding-Programmes of Europe? [The session is organised by the ETP Nanomedicine](#)

The Participants

Dr. Laurent Lévy, CEO, Nanobiotix and Co-President of the French Technology Platform on Nanomedicine Paris (F)

Dr. rer. nat. Andreas Jordan, CSO, magForce Nanotechnologie AG, Berlin (D)

Dr. Heinrich Rohrer, Nobel Laureate Physics 1986, Wollerau (CH)

Dr. Neil P. Desai, Senior Vice President, Global research & Development, Abraxis BioScience, Los Angeles (USA)
Prof. Dr. med. Christoph Alexiou, Head Division for Experimental Oncology and Nanomedicine at the Department of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital Erlangen (D)
Dr. med. Isabelle Thizon-de Gaulle, Vice President “Scouting and Partnering R&D” France, Sanofi-Aventis, Paris (F) (to be confirmed)
Dr. med. Richard Peck, Global Head Clinical Pharmacology, F. Hoffman-la Roche, Welwyn Garden City, (UK)

13.00 Lunch

Plenum

14.15 **11. The Politicians Statements to Nanomedicine**
Chairmen Dr. Sebastian Lange, European Technology Platform on Nanomedicine and Beat Löffler, MA, CLINAM Foundation

Statement 1 **Statements on Nanomedicine from the Swiss Parliament**
Dr. Mauro Dell’Ambrogio, Secretary of State for Education and Research of Switzerland, Berne, (CH)

Statement 2 **Statements on Nanomedicine from the European Union**
Dr. Rudolf Strohmeier, Deputy Director General of the DG for Research, Brussels (B)

Statement 3 **ETPN’s Statement: Vision Towards the Take Off of Nanomedicine in Europe**
Bertrand Loubaton, MBA, Chairman of the ETPN and Director Pharmaceutical & Academic Research, Director Strategy, Head of Innovation and Cooperation, GE Healthcare Europe, Velizy (F)

15.15 **Questions and Debate**

15.45 **Break**

16.15 **3 PARALLEL SESSIONS**
Parallel Session A (Hall 1)

16.15 **12. Nanoscience Technologies for Solving Medical Problems (3)**
Chairman NN
Statement 1 **CriPec: Translation of a Micellar Drug Delivery Platform into Pharmaceutical Products**
Dr. Cristianne JF Rijcken, Pham, CEO, Cristal Delivery BV., Utrecht, (NL)

Statement 2 **Challenges in Manufacturing and Application of Nanoparticles as Diagnostic Tool.**
Prof. Heinrich Hofmann, EPFL, Institute of Materials, Powder Technology Laboratory, Lausanne (CH)

Statement 3 **The Powerful Link between Photodynamic- and Nanomedicine**
Prof. Dr. Heinrich Walt, Group Leader, Oral Oncology Research and Vice-President of the European Platform for Photodynamic Medicine (EPPM) University Hospital Zürich, Dep.of Cranio-Maxillo-Facial Surgery, Zürich (CH)

Statement 4 **Nano-Tonometry: a New Measure for Structural Reorganization of the Eye Caused by Glaucoma**
Prof. Dr. Rutledge Ellis-Behnke, Director of the Nanomedicine Translational Think Tank Department of Ophthalmology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg (D)

Statement 5 **Smart Nanostructured Active Implants for Tissue Engineering Applications**
Dr. Nadia Jessel, PhD, HDR, Research Director, DR2 Inserm Active Biomaterials & Tissue Engineering (French National Institute for Health and Medical Research) Strasbourg (F)

17.05 **Questions & Debate**

17.40 **Short Break**

Parallel Session B (Hall 2)

- 16.15 **Panel & Debate**
Chairman **13. Ethics, Sustainability in Nanomedicine**
Prof. Dr. med. Bernice Elger, PhD, dipl. theol., Medical University Center, Geneva (CH)
- Statement 1 **The Indispensable Context between Novel Methods in Science and Ethics**
Prof. Dr. Hans-Peter Schreiber, Professor em. for Bioethics, ETH Zürich (CH)
- Statement 2 **Growth and Ethics in Nanomedicine - Long Return on Investment and Sustainable Development**
Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine, Basel (CH)
- Statement 3 **How to keep Ethics in Nanomedicine Within Daily Life and Work Routine**
Dr. Klaus-Michael Weltring, Director, Network Bioanalytik, Münster (D)
- Statement 4 **What's the Good of Nanomedicine – and Should it Lead the Enhancement?**
Dr. Donald Bruce, Edinethics Ltd., Edinburgh, Scotland (UK)
- 17.00 **Questions and Debate**
- 17.40 **Short Break**

Parallel Session C (Hall 3)

- 16.15 **14. Nanoscience Technologies for Solving Medical Problems (4)**
Chairman NN
16.15 **Five Submitted Statements**
- 17.05 **Questions & Debate**
- 17.40 **Short Break**

Plenum

- 17.55 **15. Late Breaking and Ongoing Trials in Nanomedicine (2)**
Chairman NN
- Statement 1 **Nanomedicine for Development of Therapeutic Vaccines against Infectious Diseases, Immunological Disorders and Cancer**
Prof. Dr. Julianna Lisziewicz, President, Genetic Immunity, Budapest (H)
- Statement 2 **Clinical Impact of Albumin on Drug Delivery**
Dr. Felix Kratz, Head of the Division of Macromolecular Prodrugs, Tumor Biology Center, Freiburg (D)
- Statement 3 **Pre-clinical and Clinical Development of Transbuccal Insulin-GNP**
PD Dr. Jan Mous, CEO PharMida AG and COO Midatech Ltd, Muttenz (CH)
- Statement 4 **Immunostimulatory Nanoparticles for the Treatment of Allergic Asthma: Results of a Placebo-controlled Phase II Study**
Dr. Wolfgang A. Renner, CEO, Cytos Biotechnology Ltd, Schlieren (CH)
- Statement 5 **Recent Trends in Dendrimer Based Nanomedicine and Drug Delivery**
Prof. Dr. Donald Tomalia, Director of the National Dendrimer & Nanotechnology Center, Central Michigan University, Mt. Pleasant (USA)
- 18.45 **Questions and Debate**

- 19.15 **End of Second Day / Apéritif**
- 20.30 **Speakers Dinner**

Wednesday, May 25, 2011 (Registration from 07.45 am until 1.00 pm)

Plenum

- 08.15 **Keynote Lecture**
Why We Are Not the Slaves of Our Genes: a Novel Aspect of Nanobiology
Prof. Dr. Gottfried Schatz, Prof. em. for Biochemistry, Biozentrum, University Basel, (CH)

08.55 **Changing Halls**

09.00 **3 PARALLEL SESSIONS**
Parallel Session A (Hall 1)

- 09.00 **Panel & Debate**
16. Where Size matters - Nanodrugs: Definition, Action, Self Assembly
Chairman Prof. Dr. Jan Mollenhauer, University of Southern Denmark Head Molecular Oncology Director of Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN, Odense (DK)

Introduction

For classification and definition of testing requirements, a concise definition of the term “Nanodrugs” is necessary. The necessity is, for example, defined by the fact that toxicological knowledge about engineered nanoparticles is very limited. Traditional toxicology may not allow for a complete understanding of the impact of size, shape, composition and aggregation-dependent interactions of nanostructures with biological systems.

On the other hand, in the history of drug development many molecules developed as potential drug candidates had to be abandoned despite substantial efficacy, because they exhibited too strong toxicity. Conversion to nanodrugs may play an important role towards the improvement of therapeutic windows, allowing such molecules to be brought back onto the screen. More than 20 "nanodrugs" are presently on the market. What makes their performance superior to conventional approaches and are there some first lessons that we can learn from these?

- Statement 1 **Where Size Matters? - The Problems of Nanodrug Definitions**
Prof. Dr. Jan Mollenhauer, University of Southern Denmark Head Molecular Oncology Director of Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN, Odense (DK)
- Statement 2 **What Characterizes a Nanodrug?**
Prof. Dr. Costas Kiparissides, Director of the Center for Research and Technology Hellas (CE.R.T.H. and Professor of Chemical Engineering, Aristotele University of Thessaloniki, Thessaloniki (GR)
- Statement 3 **Nanotechnology for Reducing Drug Toxicity**
Prof. Dr. med. Bengt Fadeel, PhD, Institute of Environmental Medicine (IMM) Karolinska Institutet, Stockholm (S)
- Statement 4 **Today's Performance of Nanodrugs**
Prof. Dr. Rogério Gaspar, Nanomedicine & DDS group, iMed.Ul and Faculty of Pharmacy, University of Lisbon, Lisbon (P)
- Statement 5 **Manipulating Molecular Self-Assembly for Drug Development and other Technological Challenges for Nanodrug Development**
Prof. Dr. med. Ehud Gazit, PhD, Vice President for Research and Development Incumbent, Endowed Chair for Nano-Biology, Chairman of the Board, Ramot Ltd. Tel Aviv University, Tel Aviv (IL)

10.00 **Questions and Debate**

10.30 **Break**

Proposal Session & Debate

11.15 **17. ETPN-SESSION 3 The ETPN Flash Proposal Session – Present your Ideas for Collaborative Research Projects - Find partners to join your efforts!**

Chairman Nicolas Gouze, VDI/VDE Innovation, ETPN, Berlin (D)

Introduction

The 7th Framework Programme for Research and Technological Development (FP7) is the EU's main instrument for supporting collaborative research, development and innovations in science, engineering and technology, providing funding to co-finance research, technological development and demonstration projects based on competitive calls and independent peer review of project proposals. Several calls for proposals relevant for the Nanomedicine community are currently published or will be opened shortly. Other programmes such as the ERA-Net EuroNanoMed and calls on a national level are further opportunities to seek for co-funding of research efforts. **The goal of the ETPN- Flash Proposal session is to offer to the community an opportunity to briefly present their project ideas** and by that attract further project collaborators to improve or complete the consortium. The session is organised and chaired by the ETPN. A call for submission of proposals will be published shortly. Presentations shall be not longer than 5 minutes and contain a maximum of 5 slides. [The session is organised by the ETP Nanomedicine](#)

13.00 **Lunch**

Parallel Session B (Hall 2)

Panel & Debate

09.00 **18. EMA SESSION 2 Anticipation of the Future Needs regarding Nanomedicine**

Chairman Prof. Dr. Marisa Papaluca, Head of Scientific Support and Projects European Medicines Agency, London (UK)

Introduction

The Exploration of Scientific Aspects in Nanomedicine to make the right developments and regulatory considerations. This session will look at key uncertainties, both in fundamental and clinical research of nanotechnology, and at the applicability and relevance of current technical regulatory requirements.

Investigators, sponsors and regulators will discuss the joint efforts needed from all stakeholders to establish common and integrated processes to accelerate the achievements promised by Nanomedicine.

Clinicians' Statements

What We Need from the Regulators! - 4 Short Propositions from the Clinicians:

Experts' Statements:

Statement 1 **Exploring Nano-Biological Systems Encountering a Nanomedicine**

Statement 2 **Nanomedicines and First in Man Studies: Role of Non-clinical Studies and Key Regulatory Challenges**

Statement 3 **Scientific Advice and Nanotechnology: the EMA Pre-Competitive Qualification Pathway**

Statement 4 **Converging Regulatory Requirements**

[The speakers will be announced in the Final Programme](#)

10.00 **Debate**

10.30 **Break**

- 11.00 **19. Nanoscience Technologies for Solving Medical Problems (4)**
Chairman Prof. Dr. Bert Müller, Thomas Straumann Chair for Materials Science in Medicine, University Basel
- Statement 1 **Nanofluidic Technologies for Medical Diagnostics**
Prof. Dr. Giacinto Scoles, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I) and Biology Department, Temple University, Philadelphia (USA)
- Statement 2 **Silver Nanoparticles - the Real “Silver Bullet” in Clinical Medicine?**
Prof. Dr. Kenneth Kak Yuen Wong, Department of Surgery, LKS Faculty of Medicine, University of Hong Kong and Queen Mary Hospital, Hong Kong (HK/RC)
- Statement 3 **Imaging Controlled Tumor Therapy with Magnetic Nanoparticles**
Prof. Dr. med. Christoph Alexiou, Head Division for Experimental Oncology and Nanomedicine at the Department of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital Erlangen (D)
- Statement 4 **Shear Responsive Nanosystem for Cardiovascular Disease**
Dr. Andreas Zumbuehl, Assistant Professor, Department of Organic Chemistry, University of Geneva (CH)
- 11.40 **Questions and Debate**
- 12.00 **20. Nanobots, Nanoids, Nanites, Nanomachines - under research or development?**
Chairman Prof. Dr. Viola Vogel, Department of Materials Laboratory for Biologically Oriented Materials, ETH Zürich, Zürich (CH)
- Statement 1 **Nanorobotics – Medical Reality tomorrow?**
Prof. Dr. Antoine Ferreira, Head of Nanorobotics Group Control and Nanoscale Physics Modeling, Bourges, University of Orleans (F)
- Statement 2 **Top Down Approach to Intelligent Nanosystems**
Prof. Dr. Bradley Nelson, Founder and Professor of Robotics and Intelligent Systems, Leader of the Multi-Scale Robotics Lab, ETH Zürich, Zürich (CH)
- Statement 3 **Bottom Up Approach to Intelligent Nanosystems**
Prof. Dr. med. Patrick Hunziker, Dep. Chief of the Intensive Care Clinic of the University of Basel (CH)
- 12.30 **Questions and Debate**
- 13.00 **Lunch**
- Parallel Session C (Hall 3)**
- 09.00 **21. Nanoscience Technologies for Solving Medical Problems (5)**
Chairman NN
- 09.00 **Six Submitted Statements**
- 10.00 **Questions and Debate**
- 10.30 **Break**
- 11.00 **22. University Village “Small Talks” – From Research to Product and University Leadership**
Chairman NN
- 11.00 **Translation and Leadership at the Universities**
Prof. Dr. Mike Eaton, London (UK)
- 11.15 **Submitted Short Statements by Members of the CLINAM University Village 2011**

12.30 **Debate**

13.00 **Lunch**

Plenum

Looking back to the CLINAM 2010 Focus Sessions - Continuation on Cancer

14.10 **23. Medical Problems in Cancer**

Chairman

Prof. Dr. med. Simo Schwartz, Jr., PhD, Nanomedicine Coordinator Molecular Biology and Biochemistry Research Center for Nanomedicine (CIBBIM-Nanomedicine) Vall d'Hebron University Hospital Research Institute, Barcelona (SP)

14.10 **Introduction Lecture 1**

From Vision to Reality: Nanomedicine in the Oncology Practice

Prof. Dr. med. Alberto Gabizon, Hebrew University, Jerusalem (IL)

Introduction Lecture 2

14.30 **Nanomedicine - a Big Step towards Curing Cancer**

Prof. Dr. med. Simo Schwartz, Jr., PhD, Nanomedicine Coordinator Molecular Biology and Biochemistry Research Center for Nanomedicine (CIBBIM-Nanomedicine) Vall d'Hebron University Hospital Research Institute, Barcelona (SP)

14.50 **The Short Statements from the Experts**

Statement 1 **Prof. Dr. med. Patrick Hunziker**, Dep. Chief of the Intensive Care Clinic of the University of Basel, President of the European Society for Nanomedicine, Basel (CH)

Statement 2 **Dr. Neil P. Desai**, Senior Vice President, Global research & Development, Abraxis BioScience, Los Angeles (USA)

Statement 3 **Prof. Dr. med. François Berger**, Université Joseph Fourier, Director of Unit "Nanomédecine et Cerveau" of INSERM, Grenoble (F)

Statement 4 **Prof. Dr. med. Yasuhiro Matsumura**, Chief, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa City (J)

Statement 5 **Prof. Dr. Jan Mollenhauer**, University of Southern Denmark Head Molecular Oncology Director of Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN, Odense (DK)

Statement 6 **Prof. Dr. Yechezkel Barenholz**, Head, Lab of Membrane and Liposome Research Department of Biochemistry, Hebrew University - Hadassah Medical School, Jerusalem (IL)

15.30 **Questions and Debate**

16.15 **Closing remarks by the organisers**

16.30 **End of Conference 2011 and Poster visits until 17.15**

19.00 **Farewell Pizza**

General Information

Structure of the conference

The 4th CLINAM conference will take the form of a debate, where the time slot for presentations plus first question and answers is 10 -12 minutes and, after a series of talks, 30-60 minutes are reserved for interdisciplinary debates. The participants will discuss the promise and limits of nanomedical tools, techniques, and materials in the context of unsolved medical problems. The conference will also address questions of sustainability, toxicity, ethics, and the impact on society and the environment. The debates will start with

clinicians reporting unsolved medical problems in important fields related to diseases that are waiting for novel methods to improve health or to cure diseases. Based on these reports by clinicians, approaches for resolving the medical problems will be discussed from the nanotechnological point of view. In this way, the CLINAM 2011 conference will give clear views on the reality of nanotechnology applied to medicine. Due to the collaboration between CLINAM and the ETPN, regulations, policy and the future funding of Nanomedicine as well as the industrial impact will be discussed by experts from industry, science and politics.

University Village 2011

The University Village is the space for universities and research institutes, providing them with an opportunity to present novel approaches, new research projects and initial outcomes of research and experimental results as well as first patents. Researchers, engineers and industrial companies can use the foyer to show the existing tools, instruments and materials in the field of regenerative medicine, diagnostics, targeted drug delivery systems, novel materials for nanoparticles, imaging, biomaterials / biosensors / biomarkers, nanomedicine-related medical tools and medical instrumentation as well as existing nanobased clinical medications

Foyer Exhibition

The Foyer Exhibition will comprise existing tools, instruments and materials in the field of regenerative medicine, diagnostics, targeted drug delivery systems, novel materials for nanoparticles, imaging, biomaterials / biosensors / biomarkers, nanomedicine-related medical tools and medical instrumentation as well as existing nanobased clinical medications.

Nanomedicine Art Moments

Science produces sometimes art and art can often describe science. Therefore we intend to exhibit visualisations in the nanomedical field in the foyer of the conference halls. We invite you to send the best visualisation you have made in the field of Nanomedicine (600dpi required). **The emphasis is art** and not experimental details. We will have a small jury of artists and scientists and will chose the 30 best "masterpieces" and enlarge them to a format 50 x 80 cm. The participants of the conference will then vote for the best picture and author shall receive the "CLINAM Golden Palm Leaf" during the evening event. Send your work to clinam@clinam.org under the subject "Art Moments Nanomedicine" no later than until April 23, 2011 - Of course participation is facultative!

Call for papers and regulations

Deadline for submission: The deadline for submission is March 10., 2011 Scientific fields Papers submitted must cover original research aimed at future or current **clinical application of nanoscience**. This includes clinical trial designs, reports of ongoing and completed clinical trials, preclinical work, and technology papers with a clinical long-term vision. Submitted papers will undergo peer grading. Accepted papers are chosen for oral **or** poster presentation. The session topics will include: • Rheumatic disease • Cardiovascular disease • Cancer • Gastrointestinal/hepatic disease, • Bacterial infection, • Viral infection • Parasitic infection, • Implant infection, • Multiresistant bacteria, • Tuberculosis • HIV, etc. Available sessions: **1.** Sessions on clinical topics: Nanomedicine for cardiovascular disease, rheumatic disease, oncology, gastrointestinal/hepatic disease, bacterial infection, viral infection, parasitic Infection, implant infection, tuberculosis, haematology, neurology / neurosurgery, implants, inflammation, orphan diseases, dermatology, eye disease, ear disease, tissue repair, orthopaedics and many others. **2.** Sessions on technology: Nano-systems, nanoparticles, nanoanalytics and diagnostics, toxicology, nano-imaging, targeted drug delivery using nanoparticles, GMP and quality assurance, and others, propositions for solving a medical problem in a novel way by the use of nanotechnology, novel concepts and ideas if they can be supported by thorough reasoning and could lead to novel research and solutions. **3.** Sessions on the implications: Implications of nanomedicine for society, developing countries, the environment, risks and benefits, public health finance and other subjects. **4.** Session on strategy building and policy processes in Nanomedicine, Strategic approaches towards establishing a unified funding area for nanotechnologies for medical research. Policy processes to foster European leadership in Nanomedicine Submission format and Procedure: The submission must be written in Microsoft Word, RTF, or Open document file format, using Times New Roman 12 point font size with single spacing and must not run to more than three pages, including metadata and figures (one figure is obligatory). All illustrations, figures, and tables are placed within the text at the appropriate points. Make sure that margins left and right are at least 2 cm. Please mail your document to submission@clinam.org by March 10, 2011 at the latest. A receipt message will be sent to you within one week. Presentation Times and Size of Posters: Posters will be located in the Foyer viewable for all conference attendees. Due to the full conference schedule the meeting breaks and lunches will be the preferred time to study the posters. Therefore during lunch and breaks the authors are asked to be present near their poster. Posters are to be presented in the size of 1.40 meter wide and 1.00 meter high. (On notification you may bring 2 sheets). Notification and Billing: We will notify the acceptance or declination of your poster by March 20 in a letter with detail instruction how to again upload your presentation and registration and billing modes. Poster Installation on May 22 and 23: The posters have to be installed on Monday, May 23 as from 07.15 am until 08.45 am at latest. Those arriving early may also place their poster on Sunday, May 22 between 2.00 pm and 4.00 pm *Support:* If you need any help for the procedure then do not hesitate to contact us and write to loeffler@clinam.org or marty@clinam.org.

Small Talk Sessions

Posters and results are eligible for presentations in a special session of **Small Talks**, 4 minutes in length and serving to highlight the research activities in Nanotechnology in Health. The Small Talk must comprise a maximum of three slides, • **Slide 1:** general introduction to the topic of your field, presented in a way that is accessible to the highly interdisciplinary audience • **Slide 2:** some of the highlights of submitters work and institutions work • **Slide 3:** the prove how the work at the University/Institute fits into the area of Nanomedicine including showing the future.

Responsible Organiser

The European CLINAM Foundation for Clinical Nanomedicine, Basel, Switzerland (www.clinam.org) in collaboration with the European Society for Nanomedicine and the European Technology Platform on Nanomedicine (ETPN), the European Science Foundation (ESF) and the European Medicines Agency (EMA)

Responsibility

Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine and
Prof. Dr. med. Patrick Hunziker, MD, CSO of the European Foundation for Clinical Nanomedicine
Dr. Sebastian Lange, Managing Director of the European Technology Platform on Nanomedicine, Berlin (D)

Office

European Foundation for Clinical Nanomedicine

Alemannengasse 12, P.O. Box, CH-4016 Basel, Switzerland
Phone: + 41 61 695 93 95
Fax: + 41 61 695 93 90
Mail: clinam@clinam.org

The people behind the organizers

European Foundation for Clinical Nanomedicine

The CLINAM-Foundation is a non profit organisation that brings together the leading physicians in Nanomedicine on a European and international level; it provides a network for actively engaged professionals in clinical nanomedicine. The *CLINAM-Foundation* fosters the interdisciplinary cooperation of medical doctors with experts from research and industry in other fields of life sciences. Its purpose is to accelerate specifically the genesis of innovation within translational nanomedicine.

The Board of Trustees of the European Foundation for Clinical nanomedicine

Dr. iur. Alexander Gutmans
Prof. Dr. med. Patrick Hunziker
Beat Löffler, MA
Prof. Dr. Hans Joachim Güntherodt
Susy Hunziker, lic. phil.
Prof. Dr. med. Matthias Pfisterer
Prof. Dr. med. Stephan Marsch
Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)

The Members of the Advisory Board of the CLINAM-Foundation

Prof. Dr. med. Christoph Alexiou, Experimental Oncology and Nanomedicine, University Hospital Erlangen (D)
Prof. Dr. Dr. h.c. Zhores Alferov, Physicist, Nobel Laureate, Moscow
Prof. Dr. Werner Arber, Biologist and Biophysicist, Nobel Laureate, Basel
Prof. Dr. med. Jacques André Bazex, Member of the FANM, Toulouse
Patrick Boisseau, CEA-Leti-Minatec, Member of the Board of ETPN, Grenoble
Prof. Dr. Dr. h.c. Fritz Bühler, European Centre for Pharmaceutical Medicine (ECPM), Basel
Dr. med. Victor Brantl, M.Sc., Vice President, R&D Mepha Ltd, Aesch,
Dr. Andreas Burckhardt, Director of the Basel Chamber of Commerce, Basel
Dr. Peter Burckhardt, CEO, EVA The Basel Life Sciences Start-up Agency, Basel
Dr. Beat Butz, Coordinator of the Swiss National Foundation, Bern
Prof. Dr. med. Jacques Chambon, French Academy of Sciences, Strasbourg/Paris
Prof. Dr. med. Patrick Couvreur, Centre d'études Pharmaceutiques (CNRS), Paris

Dr. Christoph Eymann, Member of the Governing Council of the Canton of Basel, Basel
 Prof. Dr. Peter Gehr, Chair of the Institute of Anatomy, University Bern, Bern
 Prof. Dr. Theodor Guentert, Scientific Advisor and Senior Vice President at F. Hoffmann-La Roche Ltd., Basel
 Prof. Dr. Gerda Huber, Director of School of Life Sciences, Muttenz, Switzerland
 Prof. Dr. Silke Krol, Director of the NanoBioMed Center for Molecular Biology, Trieste
 Prof. Dr. Kostas Kostarelos, Chairholder Nanomedicine, University of London
 Prof. Dr. Karl J. Lackner, President, German Association for Clinical Chemistry and Laboratory Medicine, Mainz
 Prof. Dr. Jean Marie Lehn, ISIS, Université Louis Pasteur, Strasbourg and Collège de France, Paris, Nobel Laureate
 Prof. Dr. med. Klaus Lindpaintner, MPH, Vice President, R&D and CSO, Strategic Diagnostics Inc. Newark, USA
 Prof. Dr. Stergios Logothetidis, Aristotele University of Thessaloniki,
 Prof. Dr. med. Peter Meier-Abt, Vice-principal and Head of Research, University of Basel
 Prof. Dr. Hans Myhre, Surgeon at the University Hospital, Oslo
 Dr. Romeo Paioni, Head of Scientific and External Affairs, Novartis, Basel
 Dr. Heinrich Rohrer, Physicist, Nobel Laureate, Wollerau
 Dr. med. Dieter Scholer, Member of the Swiss Academy of Medical Sciences, Basel
 Prof. Dr. Christian Schönenberger, Director of the Swiss Nanoscience Institute, Basel
 Peter Schönherr, Ambassador of the Netherlands, Berne
 Prof. Dr. med. Jürg Schifferli, Head Internal Medicine, University Hospital Basel, Basel
 Prof. Dr. Giacinto Scoles, Biochemist and Physicist, University of Princeton (USA) and Trieste
 Prof. Dr. Joachim Seelig, Biozentrum, Basel
 Prof. Dr. Paul Siffert, Secretary General, European Research & Materials Society, (EMRS) Strasbourg
 Dr. Frank Sinner, Director of the BioNanoNet-Research Society, Graz
 Prof. Dr. med Janos Szebeni Head Department Nanomedicine, Bay Zoltán Institute, Budapest
 Prof. Dr. Donald Tomalia, Director of the National Dendrimer & Nanotechnology Center, Central Michigan University
 Dr. med. Panagiotis Trohopoulos, Cardiologist and Nano-Physician, Thessaloniki.

European Society for Nanomedicine

The European Society for Nanomedicine was set up by the CLINAM-Foundation and enjoys a large influx of members. The society is, a non profit organisation being an interdisciplinary academic society with the focus of clinical application of Nanomedicine. Since Nanomedicine is a highly interdisciplinary area of studies it brings together the physicians, biologists, pharmacologists, chemists, and biochemists as well as people with particular interests in Nanomedicine and its applications. Presently the society has more than 250 members. The Executive Structuring Council consists of the following persons: • Prof. Dr. med. Patrick Hunziker • Beat Löffler, MA • Prof. Dr. med. Jacques-André Bazex • Dr. Frank Sinner • Prof. Dr. med. Hans Myhre • Prof. Dr. Gert Storm • Prof. Dr. Joachim Seelig • Prof. Dr. med. Dr. h.c. Fritz Bühler • Prof. Dr. med. Jacques Chambron.

The European Technology Platform on Nanomedicine

The **ETP Nanomedicine** is the initiative led by industry and set up together with the European Commission, addressing the **application of nanotechnology to achieve breakthroughs in healthcare**. The ETP supports its members in **coordinating their joint research efforts and improving communication** amongst the members as well as towards the European Commission and the European Member States. The Policy Objectives are to • Establish a clear strategic vision in the area resulting in a Strategic Research Agenda • Decrease fragmentation in nano-medical research • Mobilize additional public and private investment • Identify priority areas • Boost innovation in nanobiotechnologies for medical use.

Three key priorities have been confirmed by the stakeholders: • Nanotechnology-based diagnostics including imaging • Targeted drug delivery and release • Regenerative medicine. Furthermore, the dissemination of knowledge, regulatory and IPR issues, standardization, ethical, safety, environmental and toxicity concerns, as well as public perception in general and input from other stakeholders such as insurance companies or patient organizations play an important role.

The ETPN Executive Board

• **Bertrand Loubaton**, Director Pharmaceutica & Academic Research Collaboration, Director Strategy, Head of Innovation and Cooperation, GE Healthcare Europe, Velizy, (F) • **Dr. Jürgen Simon** Director Strategy, Head of Innovation and Cooperation Siemens AG Healthcare, Erlangen, (D) • **Patrick Boisseau**, Programme Manager Nanomedicine, Nanomedicine Research Fellow CEA, Grenoble (F) • **Dr. Adriele Prina-Mello**, CRANN - Naughton Institute Trinity College Dublin, (IRL) • **Prof. Mike Eaton**, London, UK • **Prof. Costas Kirissides**, Director of Central Administration / Chairman of the Board of Directors C.E.R.T.H. ,Athens,.(GR) • **Prof. Flavio Forni**, Full professor in pharmaceutical technology, University of Modena and Reggio Emilia, (I) • **Dr. Cem Bozkurt** CEO, Alvimedica Medical Technologies, Istanbul, (TR) • **Dr. Joan-Albert Vericat**, Associate Professor of Legal Governance, NOSCIRA S.A., Madrid, Spain • **Prof. Bärbel Dorbeck-Jung**, University of Twente, (NL) **Maaike van Velzen**, Senior Director, IP

Creation - BG Healthcare, Managing Director, Philips Intellectual Property & Standards, Best, (NL) **Dr. Klaus-Michael Weltring**, Bioanalytik-Münster e.V., Münster, (D) **Dr. Sebastian Lange**, VDI/VDE-IT, Berlin (D)

The European Science Foundation

The European Science Foundation (ESF) is an independent non-governmental organisation, the members of which are 79 national funding agencies, research-performing agencies, academies and learned societies from 30 countries. The strength of ESF lies in the influential membership and in its ability to bring together the different domains of European science in order to meet the challenges of the future. Since its establishment in 1974, ESF, which has its headquarters in Strasbourg with offices in Brussels and Ostend, has assembled a host of organisations that span all disciplines of science, to create a common platform for cross-border cooperation in Europe. ESF is dedicated to promoting collaboration in scientific research, funding of research and science policy across Europe. Through its activities and instruments ESF has made major contributions to science in a global context. The ESF covers the following scientific domains: •Humanities • Life Earth and Environmental Sciences • Medical Sciences •Physical and Engineering Sciences •Social Science •Marine Sciences • Nuclear Physics • Polar Sciences • Radio Astronomy Frequencies • Space Sciences

The European Medicines Agency

The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. To ensure that the system works effectively, the Agency works closely with its partners and stakeholders, and is a proactive member of important networks in Europe and beyond.

Accommodation

The official conference hotel is the Swissôtel Le Plaza**** under the same roof with the congress Center. All participants have a special room rate of CHF 285. – (about 220. – Euro), if **indicating their participation in the Nanomedicine-Conference**. Booking: Swissôtel Le Plaza, CH-4005 Basel, phone +41 61 555 3731 E-Mail: reservations.basel@swissotel.com Other hotels can be provided through Basel Tourism: 4-star hotels CHF 180.00 - 220.00, 3-star hotels: CHF 150.00-180.00, 2-star hotels: CHF 130.00 - 150.00 Booking through: Basel Tourism Tel. +41 61 268 68 58 online on www.basel.com under “accommodation”.

Conference Fees

Registration:	Regular		Late		1 Day		1 Day Late	
Currency is EURO	Until	After	Until	After	Until	After	Until	After
	30.4. 2011	1.5.2011	30.4. 2011	1.5.2011	30.4. 2011	1.5.2011	30.4. 2011	1.5.2011
Academy member	580. --	640. --	230. --	275. --	230. --	275. --	230. --	275. --
Academy regular	750. --	825. --	300. --	360. --	300. --	360. --	300. --	360. --
Industry member	900. --	990. --	360. --	450. --	360. --	450. --	360. --	450. --
Industry regular	1'050. --	1'140. --	420. --	510. --	420. --	510. --	420. --	510. --
Student member	385. --	425. --	145. --	175. --	145. --	175. --	145. --	175. --
Student Regular	490. --	540. --	195. --	235. --	195. --	235. --	195. --	235. --

Your contribution to the Official Evening Event: 50 €
Please note: A surcharge 20% will be added for registration on site

When receiving your registration the Organiser will send you an invoice

We prefer web-registration (www.clinam.org) however we also accept scanned documents by E-mail and Fax transmissions

Changes of the Conference programme

This programme is subject to changes

Liability for Exhibition and University Village

A general liability insurance has been signed for the duration of the conference by the organiser. However this does not include damages or theft of goods within the exhibition and the university village or in the conference halls.

CLINAM 2011

European Foundation for Clinical Nanomedicine, Alemannengasse 12, P.O. Box 4016 Basel, Switzerland

Phone +41 61 695 93 95 Fax +41 61 695 93 90 Email: clinam@clinam.org website www.clinam.org

4th European-Conference for Clinical Nanomedicine CLINAM 2011

The Great Strides towards the Medicine of the Future

Monday, May 23, 8.45 am – Wednesday, May 25, 2011, 4.30 pm

Conference Registration Form

I register for the **Fourth European Conference for Clinical Nanomedicine.**

Regular

Member

Academy

Industry

Students

I participate in the **evening event** on May 23, 2011 at the support rate of 50. -- €

Title _____ Last name _____ First name _____

Profession _____ Company / University _____

Department / Affiliation _____ Address _____

ZIP code _____ Town _____

Country: _____ Phone _____

Fax: _____ E-Mail _____

Legally binding Signature: _____ Date: _____

Conference Fees

Registration:	Regular	Late	1 Day	1 Day Late
Currency is EURO	Until	After	Until	After
	30.4. 2011	1.5.2011	30.4. 2011	1.5.2011
Academy member	580. --	640. --	230. --	275. --
Academy regular	750. --	825. --	300. --	360. --
Industry member	900. --	990. --	360. --	450. --
Industry regular	1'050. --	1'140. --	420. --	510. --
Student member	385. --	425. --	145. --	175. --
Student Regular	490. --	540. --	195. --	235. --

Your contribution to the Official Evening Event: 50 €

Please note: A surcharge 20% will be added for registration on site

When receiving your registration the
Organiser will send you an invoice

We prefer web-registration (www.clinam.org) however we also accept scanned documents by E-mail and Fax transmissions

Send Registration to the European Foundation for Clinical Nanomedicine, Alemannengasse 12, P.O. Box, CH-4016
Basel, Switzerland, Phone + 41 61 695 93 95 Fax +41 61 695 93 90 E-Mail clinam@clinam.org

4th European-Conference for Clinical Nanomedicine CLINAM 2011

The Great Strides towards the Medicine of the Future

Monday, May 23, 8.45 am – Wednesday, May 25, 2011, 4.30 pm

EXHIBITION AND UNIVERSITY VILLAGE REGISTRATION FORM

Please note that there is a limitation of space and a maximum of 60 Universities shall be admitted.

For the Foyer Exhibition the space is limited to 50 companies. Booths will be assigned on a first come-first served basis.

You shall receive after your registration within 10 days a confirmation from the CLINAM Organising Office.

I herewith register as a participant within the

Foyer Exhibition (for Companies, Industrial Institutes, Societies, Network Groups)

University Village (for Universities, University-Institutes and Research Labs)

I register as: **Company** **University**

Company name / University Name

Responsible: Last Name First Name

Address

Zip Town Country

Phone Fax

..... Email

Pricing for Exhibitors

- Exhibition Space per m²**, minimum space 4 m², maximum space 20 m² 280.-- €
Exhibition Space: I book m² (please indicate in letters)
Setting: (x by y meter)
- Booth construction per m²**, minimum size 6 m², includes
1 table, 2 chairs, power connection, booth labelling 160.-- €
- Transferable Exhibitor Conference Ticket: **It includes the lunches and
the CLINAM-Evening Event for one person** 770.-- €

Pricing for University Village

- Village table (23-25 May)** incl. 1 Table, 2 chairs, 1 pinboard for poster, Power connection, and one transferable conference badge and lunch 550.-- €

For all optionals and furnishing, please send request to the Exhibition Organisers' Office Congress Plus,
Rosemarie Marty, contact@congress-plus.ch

Place, Date

Legally binding Signature and Company Stamp / University Stamp

Please send registration by E-mail, Mail or Fax to the organisers' office (clinam@clinam.org) or +41 61 695 93 90)

European Foundation for Clinical Nanomedicine, Alemannengasse 12, CH 4016 Basel, Switzerland

Phone +41 61 695 93 95 Fax + 41 61 695 93 90 Email: clinam@clinam.org Homepage: www.clinam.org

4th European Conference for Clinical Nanomedicine CLINAM 2011

The Great Strides towards the Medicine of the Future

What to expect of the 4th European-Conference for Clinical Nanomedicine?

- Unsolved Problems, Technologies at Hand and Late Breaking Trials in Clinical Nanomedicine
- 2 Regulation Sessions of the European Medicines Agency (EMA)
- 2 European Technology Platform on Nanomedicine (ETPN) Strategy and Roadmap Sessions
- ETPN Proposal Sessions: Your Ideas for Collaborative Research Projects - Find partners
- CLINAM 2011 University Village and CLINAM Foyer Exhibition

SPONSORS OF THE 4th EUROPEAN CLINAM CONFERENCE



University of Basel



FONDS NATIONAL SUISSE
SCHWEIZERISCHER NATIONALFONDS
FONDO NAZIONALE SVIZZERO
SWISS NATIONAL SCIENCE FOUNDATION



H. LEIDENFROST AG • DISCOUNT PRINT
MEDIENGESTALTUNG • DIGITALDRUCK • OFFSETDRUCK • FINISHING

CH-4058 BASEL • GRENZACHERSTRASSE 34 / BURGWEG 4
TEL. 061 691 61 33 • FAX-10 • druck@discountprint • www.discountprint.ch



Löffler&Associates
Concept Engineering